HomeAI · summaries
Storia in 2 fonti
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni
Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research and development. Global regulatory changes favor Indian players. The market is not yet fully recognizing this innovation pivot and the quality of talent driving it. GLP-1 drugs and supply chain diversification also present substantial growth potential.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni
Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced…
- ·
timesofindia.indiatimes.com
India's pharma ambitions are expanding. Are leadership capabilities keeping pace?
India makes more medicine than almost any country on earth. It is the third largest pharmaceutical producer in the world by volume and the single biggest supplier of generic…